Erik S Falck-Pedersen

US Patent:

6525029, Feb 25, 2003

Filed:

Oct 29, 1998

Appl. No.:

09/182567

Inventors:

Erik S. Falck-Pedersen - Dobbs Ferry NY
Keith Elkon - Larchmont NY

Assignee:

Cornell Research Foundation, Inc. - Ithaca NY
Hospital for Special Surgery - New York NY

International Classification:

A61K 4800

US Classification:

514 44, 4353201, 435325, 514 2, 530350

Abstract:

The present invention provides, among other things, a method of inhibiting an immune response to a recombinant vector, such as a viral vector, specifically an adenoviral vector. The method comprises contacting a cell with (i) a recombinant vector, preferably a viral vector, most preferably an adenoviral vector, comprising a transgene and (ii) a means of inhibiting an immune response to the recombinant vector selected from the group consisting of a TNF receptor fusion protein, a Fas receptor fusion protein, an IFN receptor fusion protein, a gene encoding a TNF receptor fusion protein, a gene encoding a Fas receptor fusion protein, and a gene encoding an IFN receptor fusion protein, whereupon an immune response to the recombinant vector is inhibited. In this regard, the present invention also provides a recombinant vector and a composition for use in the method.

US Patent:

6576456, Jun 10, 2003

Filed:

Jun 4, 1999

Appl. No.:

09/326447

Inventors:

Thomas J. Wickham - Bethesda MD
Erik Falck-Pedersen - Dobbs Ferry NY
Petrus W. Roelvink - Gaithersburg MD
Joseph T. Bruder - New Market MD
Jason Gall - New York NY
Imre Kovesdi - Rockville MD

Assignee:

Cornell Research Foundation, Inc. - Ithaca NY
GenVec, Inc. - Gaithersburg MD

International Classification:

C12N 701

US Classification:

4352351, 530324, 530350, 4353201, 536 231, 536 234, 536 2372

Abstract:

The invention provides a chimeric adenovirus fiber protein including a nonnative amino acid sequence, and a chimeric adenovirus fiber protein lacking a native amino acid receptor-binding sequence. The chimeric protein trimerizes when produced in a mammalian cell.

US Patent:

6599737, Jul 29, 2003

Filed:

Oct 30, 2000

Appl. No.:

09/699314

Inventors:

Erik S. Falck-Pedersen - Dobbs Ferry NY

Assignee:

Cornell Research Foundation, Inc. - Ithaca NY

International Classification:

C12N 15861

US Classification:

4353201, 435 6, 435 691, 4352351, 435325, 435 914, 435 9141, 435 9142, 435456, 536 231, 536 241, 514 44, 424 932, 424 9321

Abstract:

The present invention provides an adenoviral gene transfer vector comprising a first fiber gene and a second fiber gene, wherein the fiber genes are different. The present invention also provides related recombinant adenoviral gene transfer vectors and methods of propagating an adenovirus with a fiber protein that does not bind to a native adenoviral fiber receptor.

US Patent:

6824770, Nov 30, 2004

Filed:

May 24, 1996

Appl. No.:

08/653114

Inventors:

Erik S. Falck-Pedersen - New York NY

Assignee:

Cornell Research Foundation, Inc. - Ithaca NY

International Classification:

A01N 6300

US Classification:

424 932, 435 691, 435456, 4353201, 435325, 424 931, 536 231, 536 241, 514 44

Abstract:

The invention is directed to an adenoviral vector comprising (a) at least one insertion site for cloning a heterologous gene, and, in an orientation opposite to the direction of transcription of the adenoviral region into which it is inserted, (b) a heterologous promoter positioned upstream from the insertion site, (c) a eukaryotic splice acceptor and splice donor site positioned between the promoter and the insertion site; and (c) a polyadenylation sequence positioned downstream of the insertion site. The invention also provides a host cell infected with such a vector, a method of producing a selected protein, and a method of delivering a heterologous gene to an animal heart.

US Patent:

7261885, Aug 28, 2007

Filed:

Aug 5, 2004

Appl. No.:

10/911957

Inventors:

Erik S. Falck-Pedersen - Dobbs Ferry NY, US
Jason G. D. Gall - Germantown MD, US

Assignee:

Cornell Research Foundation, Inc. - Ithaca NY

International Classification:

A61K 48/00
C12N 15/861

US Classification:

424 932, 4353201, 435 691

Abstract:

The invention provides an adenoviral vector comprising (a) at least a portion of an adenoviral genome comprising a major late transcription unit containing a terminal exon, wherein the terminal exon comprises a 5′ splice acceptor DNA sequence element and a 3′ polyadenylation signal sequence, and (b) a non-native nucleic acid sequence encoding a protein that does not contribute to the adenoviral vector entry into a host cell, wherein the non-native nucleic acid sequence is positioned within the terminal exon, such that the non-native nucleic acid sequence is selectively expressed in cells within which the adenoviral vector can replicate. The invention further provides an adenoviral vector composition and a method for treating or preventing a pathologic state in a mammal, comprising administering to the mammal the adenoviral vector composition of the invention in an amount sufficient to treat or prevent the pathologic state in the mammal.

US Patent:

20030073662, Apr 17, 2003

Filed:

Nov 8, 2002

Appl. No.:

10/291007

Inventors:

Marvin Gershengorn - New York NY, US
Erik Falck-Pedersen - Dobbs Ferry NY, US
Ronald Crystal - New York NY, US

Assignee:

Cornell Research Foundation, Inc. - Ithaca NY

International Classification:

A61K048/00
C07K014/705
C12N015/867

US Classification:

514/044000, 424/093210, 435/456000, 530/350000

Abstract:

The present invention is directed to an in vivo cell transformed with DNA encoding a cell signalling receptor not endogenous to the cell. The cell signalling receptor is capable of activating a signal transduction pathway endogenous to the cell, and the cell signalling receptor can be controllably activated thereby controllably activating the signal transduction pathway so as to regulate a cell function controlled by the signal transduction pathway. The invention also provides a method of ectopically expressing a non-endogenous receptor in a cell, and a method of regulating a cell function in vivo. The method of regulating a cell function comprises transforming a cell with DNA encoding a cell signalling receptor not endogenous to the cell, as above, and controllably exposing the cell to an extracellular molecule capable of activating the foreign cell signalling receptor. Activation of the cell signalling receptor activates the endogenous signal transduction pathway so as to regulate a cell function controlled by the endogenous signal transduction pathway.

US Patent:

20030166286, Sep 4, 2003

Filed:

Jun 17, 2002

Appl. No.:

10/173930

Inventors:

Thomas Wickham - Germantown MD, US
Erik Falck-Pedersen - Dobbs Ferry NY, US
Petrus Roelvink - Germantown MD, US
Joseph Bruder - Ijamsville MD, US
Jason Gall - Germantown MD, US
Imre Kovesdi - Rockville MD, US

Assignee:

Cornell Research Foundation, Inc. - Ithaca NY

International Classification:

C12N015/861
C12N007/00

US Classification:

435/456000, 435/235100

Abstract:

A recombinant adenovirus comprising a chimeric adenoviral fiber protein comprising a non-adenoviral amino acid sequence in place of or in addition to a native fiber amino acid sequence, wherein the chimeric adenoviral fiber protein comprises a trimerization domain and the non-adenoviral amino acid sequence is of a size such that folding of the chimeric adenoviral fiber protein and assembly of a complex comprising the chimeric adenoviral fiber protein and a penton base is not impeded, and an adenoviral transfer vector for the generation of such a recombinant adenovirus are provided.

US Patent:

20050106125, May 19, 2005

Filed:

Oct 5, 2004

Appl. No.:

10/959017

Inventors:

Erik Falck-Pedersen - Dobbs Ferry NY, US
Nicola Philpott - London, GB

Assignee:

Cornell Research Foundation, Inc. - Ithaca NY

International Classification:

A61K048/00
C12N015/861

US Classification:

424093200, 435456000, 435325000

Abstract:

The invention provides an expression construct comprising a nucleic acid sequence encoding an adeno-associated virus integration efficiency element (AAV IEE), wherein the expression construct is substantially devoid of AAV inverted terminal repeats (AAV ITRs). Such an expression construct site-specifically integrates into a host cell chromosome when provided to a host cell in conjunction with an AAV Rep protein. The invention also provides a method of integrating a nucleic acid sequence of interest into a host cell chromosome through use of such an expression construct, as well as a method of prophylactically or therapeutically treating a mammal for a pathologic state comprising administering to a mammal such an expression construct comprising a nucleic acid sequence encoding a therapeutic factor.